TY - JOUR
T1 - Molecular Neuropathology in Practice
T2 - Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma
AU - Nasrallah, MacLean P.
AU - Binder, Zev A.
AU - Oldridge, Derek A.
AU - Zhao, Jianhua
AU - Lieberman, David B.
AU - Roth, Jacquelyn J.
AU - Watt, Christopher D.
AU - Sukhadia, Shrey
AU - Klinman, Eva
AU - Daber, Robert D.
AU - Desai, Arati
AU - Brem, Steven
AU - O’Rourke, Donald M.
AU - Morrissette, Jennifer J.D.
N1 - Publisher Copyright:
© The Author(s) 2019.
PY - 2019
Y1 - 2019
N2 - Molecular profiling of glioblastoma has revealed complex cytogenetic, epigenetic, and molecular abnormalities that are necessary for diagnosis, prognosis, and treatment. Our neuro-oncology group has developed a data-driven, institutional consensus guideline for efficient and optimal workup of glioblastomas based on our routine performance of molecular testing. We describe our institution’s testing algorithm, assay development, and genetic findings in glioblastoma, to illustrate current practices and challenges in neuropathology related to molecular and genetic testing. We have found that coordination of test requisition, tissue handling, and incorporation of results into the final pathologic diagnosis by the neuropathologist improve patient care. Here, we present analysis of O6-methylguanine-DNA-methyltransferase promoter methylation and next-generation sequencing results of 189 patients, obtained utilizing our internal processes led by the neuropathology team. Our institutional pathway for neuropathologist-driven molecular testing has streamlined the management of glioblastoma samples for efficient return of results for incorporation of genomic data into the pathological diagnosis and optimal patient care.
AB - Molecular profiling of glioblastoma has revealed complex cytogenetic, epigenetic, and molecular abnormalities that are necessary for diagnosis, prognosis, and treatment. Our neuro-oncology group has developed a data-driven, institutional consensus guideline for efficient and optimal workup of glioblastomas based on our routine performance of molecular testing. We describe our institution’s testing algorithm, assay development, and genetic findings in glioblastoma, to illustrate current practices and challenges in neuropathology related to molecular and genetic testing. We have found that coordination of test requisition, tissue handling, and incorporation of results into the final pathologic diagnosis by the neuropathologist improve patient care. Here, we present analysis of O6-methylguanine-DNA-methyltransferase promoter methylation and next-generation sequencing results of 189 patients, obtained utilizing our internal processes led by the neuropathology team. Our institutional pathway for neuropathologist-driven molecular testing has streamlined the management of glioblastoma samples for efficient return of results for incorporation of genomic data into the pathological diagnosis and optimal patient care.
KW - EGFR variant III
KW - glioblastoma
KW - molecular profile
KW - neuro-oncology pathway
KW - next-generation sequencing
KW - O-methylguanine-DNA-methyltransferase promoter methylation
UR - http://www.scopus.com/inward/record.url?scp=85077306796&partnerID=8YFLogxK
U2 - 10.1177/2374289519848353
DO - 10.1177/2374289519848353
M3 - Article
AN - SCOPUS:85077306796
SN - 2374-2895
VL - 6
JO - Academic Pathology
JF - Academic Pathology
ER -